Literature DB >> 17950917

Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.

Marie Robin1, Raphaël Porcher, Renato De Castro Araujo, Régis Peffault de Latour, Agnès Devergie, Vanderson Rocha, Jérome Larghero, Lionel Adès, Patricia Ribaud, Jean-Yves Mary, Gérard Socié.   

Abstract

After allogeneic hematopoietic stem cell transplantation (HSCT), early infections represent a major cause of morbidity and mortality but little information has been previously reported on late infections. Late infection incidence and risk factors were retrospectively determined in 196 long-term survivors after HLA matched related HSCT. Patients transplanted for aplastic anemia, chronic myelogenous leukemia (CML), and acute myelogenous leukemia (AML) were included. Median follow-up was 8 years. Thirty patients died beyond the first year, causes of death were relapse (n = 10) and infections (n = 19, associated with graft-versus-host disease [GVHD] in 16 patients). Late severe bacterial (LSB) and fungal infections occurred in 30 and 8 patients, yielding to an 8-year cumulative incidence of 15 (95%CI: 10-20) and 4% (95%CI: 1-6), respectively. The majority of viral infections were hepatitis C (HCV) and VZV (8-year cumulative incidence: 10 (95%CI: 5-14) and 27% (95%CI: 20-34), respectively. Three risk factors for LSB have been identified in multiple Cox analysis: CMV status (positive recipient and negative donor) (hazard ratio [HR]: 2.5, 95%CI: 1.1-5.9, P = .033), irradiation-based conditioning regimen (HR: 3.1, 95%CI: 1.2-7.8, P = .016), and extensive chronic GVHD (cGVHD; HR: 2.9, 95%CI: 1.3-6.9, P = .013). Extensive cGVHD was the only risk factor for non-HCV viral infections in patients transplanted for AML or CML (HR: 2.7, 95%CI: 1.4-5.1, P = .002). After HSCT, patients remain at high risk of infections even late after transplantation, in particular, with the above risk factors, and required a prolonged follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17950917     DOI: 10.1016/j.bbmt.2007.07.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.

Authors:  Emilie Castermans; Muriel Hannon; Jacques Dutrieux; Stéphanie Humblet-Baron; Laurence Seidel; Rémi Cheynier; Evelyne Willems; André Gothot; Jean-François Vanbellinghen; Vincent Geenen; Brenda M Sandmaier; Rainer Storb; Yves Beguin; Frédéric Baron
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

2.  Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion.

Authors:  Martin Schmidt-Hieber; S Schwarck; A Stroux; S Ganepola; P Reinke; E Thiel; L Uharek; I W Blau
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

3.  Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation.

Authors:  Michael Osthoff; Alicia Rovó; Martin Stern; Doris Danner; Alois Gratwohl; André Tichelli; Marten Trendelenburg
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

4.  Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections.

Authors:  Elise Corre; Maryvonnick Carmagnat; Marc Busson; Regis Peffault de Latour; Marie Robin; Patricia Ribaud; Antoine Toubert; Claire Rabian; Gerard Socié
Journal:  Haematologica       Date:  2010-02-04       Impact factor: 9.941

Review 5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

6.  Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Maxim Norkin; Bronwen E Shaw; Ruta Brazauskas; Heather R Tecca; Helen L Leather; Juan Gea-Banacloche; Rammurti T Kamble; Zachariah DeFilipp; David A Jacobsohn; Olle Ringden; Yoshihiro Inamoto; Kimberly A Kasow; David Buchbinder; Peter Shaw; Peiman Hematti; Raquel Schears; Sherif M Badawy; Hillard M Lazarus; Neel Bhatt; Biljana Horn; Saurabh Chhabra; Kristin M Page; Betty Hamilton; Gerhard C Hildebrandt; Jean A Yared; Vaibhav Agrawal; Amer M Beitinjaneh; Navneet Majhail; Tamila Kindwall-Keller; Richard F Olsson; Helene Schoemans; Robert Peter Gale; Siddhartha Ganguly; Ibrahim A Ahmed; Harry C Schouten; Jane L Liesveld; Nandita Khera; Amir Steinberg; Ami J Shah; Melhem Solh; David I Marks; Witold Rybka; Mahmoud Aljurf; Andrew C Dietz; Usama Gergis; Biju George; Sachiko Seo; Mary E D Flowers; Minoo Battiwalla; Bipin N Savani; Marcie L Riches; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-02       Impact factor: 5.742

7.  Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.

Authors:  Aimee M Foord; Kara L Cushing-Haugen; Michael J Boeckh; Paul A Carpenter; Mary E D Flowers; Stephanie J Lee; Wendy M Leisenring; Beth A Mueller; Joshua A Hill; Eric J Chow
Journal:  Blood Adv       Date:  2020-04-14

8.  Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Authors:  Xuying Pei; Xiangyu Zhao; Yu Wang; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Yingjun Chang; Xiaojun Huang
Journal:  Front Med       Date:  2017-09-08       Impact factor: 4.592

Review 9.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

Authors:  Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele
Journal:  Nat Rev Clin Oncol       Date:  2012-09-04       Impact factor: 66.675

10.  A risk prediction score for invasive mold disease in patients with hematological malignancies.

Authors:  Marta Stanzani; Russell E Lewis; Mauro Fiacchini; Paolo Ricci; Fabio Tumietto; Pierluigi Viale; Simone Ambretti; Michele Baccarani; Michele Cavo; Nicola Vianelli
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.